カテゴリ： GlobalData, ドイツ, 企業調査

Fresenius SE & Co KGaA (FRE)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Fresenius SE & Co KGaA (FRE) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8012950
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：95
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; Spectra laboratories; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. Its major manufacturing plants are in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA (FRE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Fresenius SE & Co KGaA, Medical Equipment, Deal Details 14
Asset Purchase 14
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 15
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 17
Partnerships 18
Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 18
Debiotech and Fresenius Medical Care Enter into Agreement 19
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 20
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 21
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 22
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 23
Fenwal Enters Into Co-Marketing Agreement With Applied Science 24
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 25
Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 26
Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 27
Equity Offering 28
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 28
Debt Offering 29
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 29
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 30
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 31
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 32
Fresenius Raises USD300 Million in Private Placement of Notes 33
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 34
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 35
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 36
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 37
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 38
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 39
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 40
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 42
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 43
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 44
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 45
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 46
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 47
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 48
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 49
Asset Transactions 50
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 50
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 51
Acquisition 52
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 52
Fresenius Medical Care Acquires Xenios 54
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 55
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 57
Fresenius Medical Care to Acquire Nefrocontrol 58
Fresenius SE & Co KGaA – Key Competitors 59
Fresenius SE & Co KGaA – Key Employees 60
Fresenius SE & Co KGaA – Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Recent Developments 66
Strategy And Business Planning 66
Sep 29, 2017: Fresenius lays cornerstone for new building at headquarters in Bad Homburg 66
Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 68
Mar 20, 2017: Fresenius Helios opens new hospital building in Duisburg 69
Nov 22, 2016: HELIOS lays foundation stone for new hospital building in Wiesbaden 70
Apr 08, 2016: Fresenius Vamed lays foundation stone for new university hospital building 71
Financial Announcements 72
Aug 01, 2017: Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth 72
Oct 27, 2016: Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised 75
Aug 01, 2016: Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter 79
May 03, 2016: Strong start into the year – Double-digit earnings growth in constant currency – Fresenius confirms Group guidance for 2016 82
Feb 24, 2016: Outstanding 2015 financial results – 25% dividend increase proposed – Positive outlook for 2016 – New mid-term growth targets 84
Corporate Communications 88
Jul 21, 2017: Fresenius appoints Rachel Empey as Chief Financial Officer 88
Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 89
Jun 26, 2016: Fresenius appoints Stephan Sturm as new Chief Executive Officer – Ulf Mark Schneider leaves the company to pursue another opportunity 90
Legal and Regulatory 91
Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 91
Jan 26, 2017: U.S. District Court Issues Preliminary Injunction Against Premium Assistance Regulation 92
Other Significant Developments 93
Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 93
Aug 17, 2016: Fresenius Kabi investing nearly $250 million to expand plant near Chicago 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
Fresenius SE & Co KGaA, Medical Equipment, Key Facts, 2016 2
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Deals By Market, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 15
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 17
Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 18
Debiotech and Fresenius Medical Care Enter into Agreement 19
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 20
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 21
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 22
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 23
Fenwal Enters Into Co-Marketing Agreement With Applied Science 24
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 25
Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 26
Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 27
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 28
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 29
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 30
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 31
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 32
Fresenius Raises USD300 Million in Private Placement of Notes 33
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 34
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 35
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 36
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 37
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 38
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 39
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 40
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 42
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 43
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 44
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 45
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 46
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 47
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 48
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 49
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 50
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 51
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 52
Fresenius Medical Care Acquires Xenios 54
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 55
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 57
Fresenius Medical Care to Acquire Nefrocontrol 58
Fresenius SE & Co KGaA, Key Competitors 59
Fresenius SE & Co KGaA, Key Employees 60
Fresenius SE & Co KGaA, Other Locations 61
Fresenius SE & Co KGaA, Subsidiaries 61

★海外企業調査レポート[Fresenius SE & Co KGaA (FRE)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Nucor Corporation：戦略・SWOT・企業財務分析
    Nucor Corporation - Strategy, SWOT and Corporate Finance Report Summary Nucor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Jacobs Engineering Group Inc (JEC)-石油・ガス分野：企業M&A・提携分析
    Summary Jacobs Engineering Group Inc. (Jacobs) is a provider of technical professional services. The company offers a diverse range of technical, professional, and construction services to industrial, commercial, and governmental customers across the globe. Its service portfolio includes project; pr …
  • Showa Shell Sekiyu KK (5002)：企業の財務・戦略的SWOT分析
    Showa Shell Sekiyu KK (5002) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Waste Management, Inc.：企業の戦略・SWOT・財務分析
    Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Waste Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Southwestern Electric Power Co：発電所・企業SWOT分析
    Southwestern Electric Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • PellePharm Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary PellePharm Inc (PellePharm), a subsidiary of BridgeBio Inc, is a biotechnology company that develops and commercializes treatments for rare genetic dermatological conditions. The company’s lead clinical program, Patidegib, is a first-in-class topical gel formulation of a proprietary hedgehog …
  • AB SKF (SKF B)：企業の財務・戦略的SWOT分析
    AB SKF (SKF B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Biomatrica Inc-医療機器分野：企業M&A・提携分析
    Summary Biomatrica Inc (Biomatrica) is a biological stabilization products developer that offers healthcare technology products. The company offers assay design and use; omics sample collection, and transport and storage chemistry products. Its transport and storage chemistry products comprise custo …
  • Harpoon Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Harpoon Therapeutics Inc (Harpoon Therapeutics) is a biotechnology company that offers solutions for immune-oncology diseases. The company provides products portfolio such as of HPN424, prostate specific antigen and harnesses a technology named TriTAC technology. It employs TriTAC technology …
  • Eden Innovations (EDE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Eden Innovations, formerly Eden Energy Ltd, is a clean energy company that offers carbon nanotube and carbon fibre production, nanomaterial concrete admixtures, hydrogen production, and storage and transport fuel system. The company manufactures and distributes fuel systems, pumps, fuel tank …
  • KPC Pharmaceuticals Inc (600422)：製薬・医療：M&Aディール及び事業提携情報
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and special botanical drugs. It also offers drugs suc …
  • Instituto Costarricense de Electricidad：企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Wakefern Food Corp.：企業の戦略的SWOT分析
    Wakefern Food Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • FleetCor Technologies Inc：企業の戦略・SWOT・財務分析
    FleetCor Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary FleetCor Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bank of Scotland Plc：企業のM&A・事業提携・投資動向
    Bank of Scotland Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Scotland Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Guangzhou R&F Properties Co Ltd：企業の戦略・SWOT・財務情報
    Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C)：企業の戦略・SWOT・財務情報
    The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report Summary The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Corning Incorporated (GLW)-医療機器分野：企業M&A・提携分析
    Summary Corning Incorporated (Corning) manufactures and sells ceramics, specialty glasses and related materials. The company’s product portfolio includes glass substrates, which find application in LCD televisions, computer monitors and laptops; optical fibers, cable, hardware and equipment for tele …
  • Reliance Industries Ltd (RELIANCE)：企業の財務・戦略的SWOT分析
    Reliance Industries Ltd (RELIANCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Inova Diagnostics Inc-医療機器分野：企業M&A・提携分析
    Summary Inova Diagnostics Inc (Inova), a subsidiary of Werfen Life Group SAU is a medical device company that develops and commercializes new autoimmune technologies and diagnostic markers. The company's diagnostic reagent products include QUANTA Flash used for semi-quantitative determination of aut …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆